Features of KRAS-mutated patients with chronic myelomonocytic leukemia with and without blast transformation in a national (ABCMML) and international cohort (BIOPORTAL).

Melanie Weissenbacher, Klaus Geissler

Abstract read

In one paragraph

Article in Wiener medizinische Wochenschrift (1946), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Melanie WeissenbacherMedical School, Sigmund Freud University, Sigmund Freud Platz 3, 1020, Vienna, Austria.

Klaus GeisslerMedical School, Sigmund Freud University, Sigmund Freud Platz 3, 1020, Vienna, Austria. geissler.klaus@gmx.at.ORCID http://orcid.org/0000-0003-1921-7034

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Big data collected in large international cooperations nowadays allow validation of findings from traditional national patient cohorts for proving consistency. In this study we compared findings in KRAS-mutated patients of the Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML) with that from the CMML cohort documented in cBioPortal. It was consistently shown in both CMML cohorts that KRAS mutations were not associated with shorter overall and acute myeloid leukemia (AML)-free survival. In both cohorts, phenotypic features such as leukocytes, hemoglobin, and circulating blasts were not significantly different between patients with and without KRAS mutations. However, the proportion of patients with thrombocytopenia was higher in KRAS-mutated patients in the BIOPORTAL cohort but not in the ABCMML cohort. The percentage of KRAS mutations significantly increased in blast transformation (from 9.8 to 21.7%), as shown in the ABCMML cohort. These data may suggest a pathogenetic role of KRAS mutations in CMML-associated AML.

Indexed as

Blast CrisisLeukemia, Myelomonocytic, ChronicMutationProto-Oncogene Proteins p21(ras)AgedAged, 80 and overAustriaCohort StudiesFemaleHumansLeukemia, Myeloid, AcuteMaleMiddle AgedPrognosisKRAS protein, humanProto-Oncogene Proteins p21(ras)Acute myeloid leukemiaAustrian biodatabase for chronic myelomonocytic leukemiaBIOPORTALChronic myelomonocytic leukemiaKRAS

Identifiers

PMID40694264

DOI10.1007/s10354-025-01099-3

PMCPMC12380988

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.